Moderna prepares for a global launch of COVID-19 vaccine
The US Biotech firm Moderna is planning for the global launch of its COVID-19 vaccine candidate mRNA-1273, announced the company.
In addition to the upcoming phase 3 study of the COVID-19 vaccine mRNA-1273, Moderna now has four programmes in phase 2 studies, said the officials.The company has recently completed the enrollment of 30,000 participants for its phase 3 study including almost 37 per cent of participants from diverse communities.
The mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilised spike (S) protein of SARS-CoV-2. The vaccine was developed by Moderna in collaboration with researchers at the NIAID Vaccine Research Center, NIH.
The results of the vaccine’s phase 1 interim analysis, which was published in The New England Journal of Medicine, showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2.”We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world,” said the Moderna CEO Stephane Bancel.